Ioflubenzamide I-131

Drug Profile

Ioflubenzamide I-131

Alternative Names: 131-I-MIP-1145; BA-100; Iodine-123 ZK-BA; Iodine-131 ZK-BA; MIP-1145; Solazed; ZK BA

Latest Information Update: 23 Jan 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer Schering Pharma
  • Developer Molecular Insight Pharmaceuticals
  • Class Antineoplastics; Benzamides; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma

Highest Development Phases

  • Suspended Malignant melanoma

Most Recent Events

  • 22 Jan 2013 Molecular Insight Pharmaceuticals has been acquired by Progenics Pharmaceuticals
  • 07 Oct 2011 Molecular Insight Pharmaceuticals terminates a phase I trial in Malignant melanoma in USA (NCT00747825)
  • 01 Mar 2011 Bayer Schering Pharma is now called Bayer HealthCare Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top